Seeking Alpha

The FDA approves GlaxoSmithKline's (GSK) raxibacumab injection to treat inhalational anthrax, a...

The FDA approves GlaxoSmithKline's (GSK) raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores. Raxibacumab is the first monoclonal antibody approved under the FDA’s Animal Efficacy Rule, which allows findings from animal studies to support FDA approval when it is not feasible or ethical to conduct trials in humans. In this case, because inhalational anthrax is a rare and lethal disease, it is not possible to conduct adequate trials in humans.
From other sites
Comments (2)
  • Tommy_Finger
    , contributor
    Comments (320) | Send Message
     
    Note to Big Pharma: It's easier for EVERYONE if you chose easier-to-pronounce names!!
    14 Dec 2012, 04:57 PM Reply Like
  • BeachChicken
    , contributor
    Comments (266) | Send Message
     
    I'll learn to pronounce it, if it pushes up GSK
    15 Dec 2012, 03:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs